Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial  Lancet. 2025;405(10476):396-407
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39892911

Case for a health equity framework in health technology assessment  Lancet. 2025;405(10476):376-377
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39892901

Celebrating 30 years of the international network of agencies for health technology assessment (INAHTA)  International Journal of Technology Assessment in Health Care. 2025;41(1):e7
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39895096

Clinical trials for implantable neural prostheses: understanding the ethical and technical requirements  Lancet Digit Health. 2025
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39794174

Comparison of health technology assessments for digital therapeutics in Germany, the United Kingdom and France  Digit Health. 2025;11:20552076241308704
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39845519

Efficacy, safety and cost-effectiveness of obinutuzumab in patients with follicular lymphoma: a rapid review  Frontiers in Pharmacology. 2024;15:1426772
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39830356

Evidence generation throughout paediatric medicines life cycle: findings from collaborative work between European Medicines Agency (EMA) and EUnetHTA on use of extrapolation  British Journal of Pharmacology. 2025;182(3):484-494
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39574299

Financial challenges of being on long-term, high-cost medications  Neurooncol Pract. 2025;12(Suppl 1):i49-i58
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39776525

Generative Artificial Intelligence for Health Technology Assessment: Opportunities, Challenges, and Policy Considerations: An ISPOR Working Group Report  Value in Health. 2025;28(2):175-183
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39536966

Guidance for an Effective Approach to Integrated Evidence Planning in a Dynamic World  Clinical Pharmacology and Therapeutics. 2025
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39789863

Hospital-based health technology assessment (HTA) in Latin America and the Caribbean: a scoping review  Revista Panamericana de Salud Publica. 2025;49:e8
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39811043

How can actuarial science contribute to the field of health technology assessment? An interdisciplinary perspective International Journal of Technology Assessment in Health Care. 2025;41(1):e3
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39757736

MRI-assessed Dynamic Hyperinflation Induced by Tachypnea in Chronic Obstructive Pulmonary Disease: The SPIROMICS-HF Study  Radiol Cardiothorac Imaging. 2025;7(1):e240053
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39836055

Multi-cancer early detection tests for general population screening: a systematic literature review  Health Technology Assessment. 2025;29(2):1-105
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39898371

Multiple Perspectives on the Need for Real-World Evidence to Inform Regulatory and Health Technology Assessment Decision-Making: Scoping Review and Stakeholder Interviews  Pharmacoepidemiology and Drug Safety. 2025;34(1):e70074
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39777765

The Paradigm Shift From Patient to Health Consumer: 20 Years of Value Assessment in Health  Journal of Medical Internet Research. 2025;27:e60443
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39793021

Post-Market Evidence for Cancer Medicines in Regulatory and Clinical Decision-Making: A Scoping Review  Pharmacoepidemiology and Drug Safety. 2025;34(1):e70093
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39805804

Revising EU pharmaceutical legislation: will it foster drug repurposing?  Drug Discov Today. 2025;30(1):104286
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39756647

A Systematic Literature Review of Modelling Approaches to Evaluate the Cost Effectiveness of PET/CT for Therapy Response Monitoring in Oncology  Pharmacoeconomics. 2025;43(2):133-151
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39488797

A systematic review of the cost-effectiveness of anti-VEGF drugs for the treatment of diabetic retinopathy  Health Technology Assessment. 2025:1-19
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39881630

The Use of Real-World Data for Estimating Relative Treatment Effects in NICE Health Technology Assessment Submissions: A Review  Pharmacoeconomics. 2025;43(2):123-131
https://pubmed.ncbi.nlm.nih.gov/?otool=iaufhhslib&term=39520643